Literature DB >> 27966305

Efficacy of mitomycin-C and infliximab in reducing adhesionand fibrosis following strabismus surgery.

Emin Serbülent Güçlü1, Ayşe Ayça Sarı2, Erdem Dinç2, Tuba Özcan Metin3, Banu Çoşkun Yılmaz3, Bahar Taşdelen4.   

Abstract

BACKGROUND/AIM: The present study aimed to investigate the efficacy of mitomycin-C (MMC) and infliximab (INF) in reducing adhesion and fibrosis following strabismus surgery.
MATERIALS AND METHODS: Forty eyes of 20 albino rabbits were separated into MMC and INF groups. Right and left eyes of rabbits were assigned to the drug and control groups, respectively. The superior rectus muscle was disinserted, the drug was administered to the surgical area for 5 min in the drug eyes (MMC 0.2 mg/mL or INF 5 mg/mL), and physiological saline was administered to the control eyes. Surgical areas were rinsed with 10 mL of physiological saline. The disinserted muscle was then sutured to the same area using 6.0 Vicryl. The rabbits were sacrificed after 4 weeks for histopathological examination.
RESULTS: Significant reduction was observed in fibrosis in the INF group as compared to the control group (P = 0.005). Although adhesion formation in the drug eyes reduced in the MMC and INF groups as compared to the control group, the difference was not significant (P = 0.280 and P = 0.579, respectively).
CONCLUSION: This study demonstrated the fibrosis-preventing efficacy of IFN; thus, it can be a good option in reducing fibrosis in strabismus surgery.

Entities:  

Keywords:  Strabismus surgery; adhesion; fibrosis; infliximab; mitomycin-C

Mesh:

Substances:

Year:  2016        PMID: 27966305     DOI: 10.3906/sag-1506-45

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  1 in total

1.  Effects of the Rho-Kinase Inhibitor Y-27632 on Extraocular Muscle Surgery in Rabbits.

Authors:  Ji-Sun Moon; Hyun Kyung Kim; Sun Young Shin
Journal:  J Ophthalmol       Date:  2017-07-26       Impact factor: 1.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.